"Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumonia
Ventilator-associated pneumonia (VAP) places a substantial burden on healthcare systems because of its frequency and associated morbidity and hospital costs. VAP occurs at a rate of 2.5-12.3 episodes per 1,000 ventilator days 1 and occurs in 9.3%-23.5% of patients receiving mechanical ventilation. [2] [3] [4] [5] VAP adds 5-7 days to the length of stay in the intensive care unit (ICU) 4 and 10-12 days to the length of hospitalization. 2, 3 Specifically, estimates of attributable hospital costs for VAP range from $10,000 to $25,000. [3] [4] [5] [6] Because of its high clinical and economic burden, VAP is now a focus of efforts to improve outcomes and patient safety in the ICU. These efforts will become more pertinent if the Centers for Medicare and Medicaid Services adds VAP to the list of conditions that will no longer be eligible for incremental payments.
A silver-coated endotracheal tube (Agento I. C., C. R. Bard) has been developed to reduce VAP incidence. The silver coating provides broad-spectrum antimicrobial activity, 7 reduces bacterial adhesion to the endotracheal tube, 8, 9 and blocks biofilm formation on the endotracheal tube. 10 The silver ions are microdispersed in a proprietary polymer that may enhance antimicrobial activity by blocking bacterial adhesion to the endotracheal tube. [11] [12] [13] [14] The North American Silver-Coated Endotracheal Tube (NASCENT) study 15 provided clinical evidence of efficacy in 2,003 patients expected to require mechanical ventilation for x24 hours. In this randomized, controlled, pivotal trial, the silver-coated endotracheal tube resulted in a 35.9% relative risk reduction of VAP ( ), P p .03 with a cumulative incidence of microbiologically confirmed VAP of 7.5% in patients managed with uncoated endotracheal tubes and 4.8% in patients managed with silver-coated endotracheal tubes. Therefore, the estimated number of patients that must be treated with the silver-coated endotracheal tube to prevent 1 case of VAP is approximately 37 based on the 2.7% absolute risk reduction in patients intubated for x24 hours.
We hypothesized that use of silver-coated endotracheal tubes would be cost effective in patients requiring mechanical ventilation for x24 hours. Given the economic burden as- a Actual relative risk reduction of 36% seen in the NASCENT study 15 reduced by 33% to 24% in the base case. b Reported values adjusted to 2007 US dollars. 5 sociated with VAP, 2-5 routine use of an endotracheal tube capable of reducing the incidence of VAP might offset the acquisition cost of the device, resulting in savings to the hospital. To test this hypothesis, we developed a decision model to compare the costs of silver-coated and uncoated endotracheal tubes relative to those associated with the development of VAP.
methods
We compared economic outcomes in terms of VAP prevention with the use of silver-coated endotracheal tubes to outcomes with the use of uncoated endotracheal tubes in a hypothetical cohort of 1,000 patients expected to require mechanical ventilation for x24 hours. The primary end point was marginal hospital savings associated with prevention of 1 case of VAP, and it was calculated as savings in VAP hospital costs associated with use of the silver-coated endotracheal tube minus direct hospital acquisition cost of the endotracheal tube divided by the number of VAP cases prevented. This ratio represented the cost (or savings) per 1 case of VAP prevented. The secondary end point was marginal hospital savings (or costs) associated with reduced incidence of VAP over the entire 1,000-patient cohort. We followed the recommendations of the Panel on Cost-Effectiveness in Health and Medicine. 16 Model structure and inputs. We used a simple decision tree to model the outcomes. The only decision node represented the determination to use silver-coated or uncoated endotracheal tubes. We passed the 1,000-patient cohort through each branch of the decision tree separately to development of VAP or no development of VAP. The model required the following inputs: incidence of VAP, relative risk reduction of VAP with silver-coated endotracheal tube, hospital costs associated with VAP, and costs of silver-coated and uncoated endotracheal tubes (Table 1) . We used the medical care component of the Consumer Price Index 17 to adjust the estimated cost of VAP to 2007 US dollars.
Monte Carlo simulations and sensitivity analyses. We performed Monte Carlo simulations and sensitivity analyses to identify important model uncertainties and to assess the robustness of our findings across the wide range of VAP incidence in different patient populations. Each outcome was tested in 10,000 simulation trials, while the estimates were simultaneously and randomly varied across the ranges specified in Table 1 . The ranges for the incidence of VAP 4 and hospital cost of VAP 5 were bound by their corresponding published 95% confidence intervals. We varied the relative risk reduction of VAP by ‫%05ע‬ and the cost estimate of the silver-coated endotracheal tube by ‫.01$ע‬ To bias the model against the silver-coated endotracheal tube, we set the lower bound of the acquisition cost for the uncoated endotracheal tube at $0.00. We conducted sensitivity analyses to assess the univariate contribution of uncertainty in each model parameter to the variability in outcomes and subsequently completed a 2-way sensitivity analysis-simultaneously varying the 2 most influential inputs on the outcome estimate. We also tested break-even scenarios to determine circumstances under which each input was no longer associated with hospital savings and a worst-case scenario with all inputs maximally biased against the silver-coated endotracheal tube.
results
In the base-case analysis, we estimated that use of silvercoated endotracheal tubes would prevent 23 of 97 expected cases of VAP. Despite the higher acquisition cost of the silvercoated endotracheal tube, we calculated a marginal hospital savings of $12,840 per 1 case of VAP prevented, with assumed marginal VAP cost of $16,620 (in 2007 US dollars) and costs of $90.00 for silver-coated and $2.00 for uncoated endotracheal tubes. This translated to a total annualized marginal hospital savings of $298,914 for the entire 1,000-patient cohort, reducing VAP-specific hospital costs by 18.5%.
In the univariate sensitivity analysis, the model was most sensitive to VAP hospital cost, VAP relative risk reduction associated with the silver-coated endotracheal tube, and pooled cumulative risk of VAP assumptions (Figure) . Varying the hospital cost of VAP across the 95% confidence interval led to less than 25% variability in the point estimate for savings with the silver-coated endotracheal tube. Similarly, varying the relative risk reduction across the prespecified range of 12%-36% led to less than 25% variability in savings with the silver-coated endotracheal tube. The model was relatively insensitive to the acquisition costs of the silver-coated and the uncoated endotracheal tubes.
In a 2-way sensitivity analysis of the most influential inputs, use of the silver-coated endotracheal tube continued to yield In the break-even sensitivity analysis, the cost of the silvercoated endotracheal tube had to be increased to $388 to offset the savings when all other inputs were held constant at the base-case point estimates. In break-even sensitivity analyses of other inputs, VAP risk had to be decreased from 9.7% to 2.2%, relative VAP risk reduction with the silver-coated endotracheal tube had to decrease from 24% to 5.5%, or marginal VAP cost had to decline from $16,620 to $3,780 to offset the savings when all other inputs were held constant.
In the worst-case scenario with each input maximally skewed against the silver-coated endotracheal tube, the hospital cost to prevent 1 case of VAP was $4,550, with assumed VAP risk of only 7%, relative VAP risk reduction of 12%, marginal VAP cost of $7,355, and cost of $100 for the silvercoated endotracheal tube. In the worst-case scenario, the uncoated endotracheal tubes had to be free (cost of $0.00).
discussion
Our findings demonstrated the cost effectiveness of a silvercoated endotracheal tube designed to reduce VAP incidence. Although the acquisition cost of the silver-coated endotracheal tube far exceeds that of an uncoated endotracheal tube, this difference in cost was offset by the excess hospital costs associated with VAP infection. [3] [4] [5] [6] Specifically, the marginal hospital savings per 1 case of VAP prevented was $12,840, confirming that the silver-coated endotracheal tube was associated with substantial savings. Despite uncertainty associated with specific model inputs, our conclusions regarding the cost implications of the silver-coated endotracheal tube remained valid across a wide range of assumptions.
In accordance with published recommendations, 16 we intentionally biased model assumptions to favor uncoated endotracheal tubes. For example, we diminished the relative risk reduction observed in the NASCENT study 15 by onethird. We did this to simulate actual practice, where the effect size is often smaller than what is reported in controlled clinical studies that (by design) try to limit variability through precise entry criteria. Consistent with our conservative approach, we also chose the estimate for incidence of VAP from a meta-analysis of 38 prospective cohort or nonrandomized studies of 48,112 patients. 4 The pooled cumulative incidence of VAP in that population was 9.7%, which approximated the incidence in a large US database. 2 Similarly, our marginal hospital cost of VAP was based on a conservative estimate of approximately $12,000, 5 which was within the range of attributable costs calculated in the meta-analysis. 4 Higher values have been reported for both VAP incidence and VAP hospital cost. 3, 6 Of course, use of these higher inputs would have made the intervention even more cost effective.
We performed extensive sensitivity testing to capture the substantial uncertainty surrounding model inputs and the unique costs and epidemiologic situations of individual institutions. For example, VAP risk is difficult to estimate because accurate diagnosis is confounded by other frequent ICU complications that mimic the clinical appearance of VAP. 18 Consequently, clinical criteria can lead to inaccurate diagnosis and overestimation of the incidence, whereas the microbiologic criteria used in the NASCENT study 15 are not likely to be associated with this limitation. Each of our sensitivity analyses confirmed the robustness of the hospital savings associated with the silver-coated endotracheal tube over a wide range for each model input. The most influential input on the outcome estimate was marginal hospital cost of VAP. Diminishing this input to its lower 95% confidence bound, 5 however, did not alter the principal finding. Only the extreme scenario of lowest VAP cost combined with lowest VAP relative risk reduction failed to yield savings. Nonetheless, the additional expenditures required for use of the silver-coated endotracheal tube were modest and totaled only $205 to prevent 1 case of VAP.
The marginal hospital savings associated with use of the silver-coated endotracheal tube was at least comparable to that of other prevention strategies generally employed in the ICU and to that of specific VAP prevention strategies. For example, continuous subglottic suctioning saves $1,924 per case of VAP prevented. 19 An infection control strategy comprising intensive surveillance and interventions saves approximately $5,300 per case. 20 Oral decontamination with various antibiotic preparations saves $13,430 per case. 21 In contrast with other prevention strategies, the use of the silvercoated endotracheal tube was supported by data from a large prospective randomized trial, whereas the quality of the data supporting these alternative strategies is more limited.
Successful implementation of prevention strategies typically requires a multidisciplinary team, 22 staff education, 23, 24 and adequate staffing levels, 25 all followed by continuous vigilance and surveillance to maintain success. 26 Unfortunately, nonadherence is common among both physicians 27 and nurses, 28 suggesting a practical advantage for use of the silvercoated endotracheal tube. Because its efficacy does not rely on behavioral changes by healthcare providers or procedural changes within the ICU, the silver-coated endotracheal tube becomes user independent after placement. This in turn removes an important component of process of care from the patient safety equation and is consistent with efforts to alter culture in the ICU.
Our pharmacoeconomic analysis had several limitations. First, only 1 clinical study was used to estimate relative risk reduction of VAP with use of silver-coated endotracheal tubes; however, the NASCENT study 15 was the largest randomized study of the impact of an endotracheal tube on incidence of VAP. Use of the silver-coated endotracheal tube was not associated with decreased length of hospital stay in the NAS-CENT study. 15 Failure to detect between-group differences in length of stay, one of the most important drivers of economic outcome, is not surprising in view of the low incidence of microbiologically confirmed VAP. Furthermore, the pivotal study was not powered to detect between-group differences in secondary end points. Second, the model assumed that all types of VAP have similar financial implications. In other words, the costs of VAP due to Pseudomonas aeruginosa may not be the same as those due to methicillin-susceptible Staphylococcus aureus. To address this, we altered the cost estimates for VAP extensively and found that the hospital savings persisted. Similarly, the model did not differentiate between early-and late-onset VAP, which also may have different financial implications. In clinical practice, however, most cases of VAP occur during the first 7-8 days of intubation because the median duration of intubation is less than 10 days 29 and more than 75% of tubes are removed before 10 days. 30, 31 Third, we quantified cost effectiveness from the hospital perspective. Modeling from the societal perspective would not necessarily have diminished the cost effectiveness of the silvercoated endotracheal tube because it is unclear whether VAP is associated with attributable mortality. In fact, consideration of long-term, patient-reported complications of VAP probably would have augmented our findings.
Finally, there are likely hidden costs that we could not consider. Conversely, there are potential savings that we could not specifically model. For example, decreased VAP rates may help prevent the spread of antimicrobial resistance. From the throughput perspective, preventing VAP may facilitate bed turnover in the ICU and thus help eliminate bottlenecks that impede access to appropriate care.
Our pharmacoeconomic findings, combined with previous data demonstrating clinical benefit, indicated that use of a silver-coated endotracheal tube represents a strategy for preventing VAP that may result in savings to the hospital or healthcare system. Importantly, the silver-coated endotracheal tube becomes user independent after intubation and does not add to the burden of the healthcare provider. Collectively, these findings suggested that routine use of the silver-coated endotracheal tube among patients expected to require mechanical ventilation for x24 hours could have important public health implications.
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